Skip to content
DataLookout
Menu

PAT-DANCT06731621

Psilocybin for Treatment-Resistant Depression in Autism

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 85 words Show 5 more changesShow less
    • Primary endpoints: details revised at 2 of 4 entries
    • Final enrollment: 18 participants (planned 20)
    • Primary and study completion dates: Dec 2026 to Jan 2027
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description expanded, about 179 words
  2. Minor Enrollment closed, study ongoing
    • Primary and study completion moved earlier from Aug 2027 to Dec 2026
    • Site details revised
    v5
  3. Notable Eligibility criteria expanded, about 93 wordsv3 Show 4 more changesShow less
    • Primary endpoints: 3 to 4
    • Secondary endpoints: 3 to 2
    • Study description expanded, about 545 words
    • Study title shortened, about 9 words
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 2024 to Nov 1, 2024
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Feasibility of Administering Psilocybin in Conjunction with Psychotherapy in Autistic Adults
Timeframe: From enrollment to end of treatment & follow-up at 12 weeks post-intervention (12 weeks post treatment dosing i.e., Day 0)
Subjective Psychedelic Effects as Measured by the 11-Dimensions of Altered States of Consciousness (11D-ASC) Rating Scale
Timeframe: Administered following each dosing session (Visit 3 (Safety dosing - Day -7)) & Visit 4 (treatment dosing - Day 0))
Number of Participants with Treatment-Related Adverse Events as Assessed by SBQ-ASC & UKU Side Effect Rating Scale
Timeframe: From enrollment to end of treatment & follow-up at 12 weeks post-intervention (12 weeks post treatment dosing i.e., Day 0)
Feasibility of Dense Sampling Brain MRI Procedures & Trial Design
Timeframe: From enrollment to end of treatment & follow-up at 12 weeks post-intervention (12 weeks post-treatment dosing i.e., Day 0)

Secondary (2)

Changes in Brain Network Interactions as Assessed with Pre- and Post-Intervention MRI Brain Scans
Changes & Variance in Brain Functional Connectivity Assessed Across Dense Sampling Brain MRI Sessions

Arms and interventions

Open-labelExperimental

Safety Dosing Session (V3): 10mg of psilocybin + therapy + safety evaluations Active Treatment Session (V4): 25mg of psilocybin + therapy + safety evaluations

Drugs: Psilocybin

Sites

1 site in 1 country

  • Centre for Addiction and Mental HealthToronto, Ontario, Canada